5th Century Partners Exits Radon Medical Imaging with Sale to Leonard Green

5th Century Partners completed the sale of Radon Medical Imaging to Leonard Green & Partners; financial terms were not disclosed. During 5CP's investment period, Radon more than tripled revenue, expanded from five states to 26 and grew to over 220 employees, supported by four acquisitions from 2022 through 2025. The transaction marks Radon's next ownership phase after scaling into a multi-state medical imaging services platform.

Analysis

The strategic signal is a sponsor-to-sponsor handoff of a scaled independent imaging-service platform—not evidence, by itself, of a sector-wide valuation mark or a public-equity catalyst. If Radon’s expansion reflects repeatable integration economics, LGP may pursue further acquisitions, increasing competition for regional service businesses and potentially accelerating consolidation in outsourced imaging maintenance. A larger independent platform could pressure OEM service economics at the margin, but hospitals’ equipment complexity, uptime requirements, and OEM-specific expertise limit straightforward substitution; OEMs such as GE HealthCare, Siemens Healthineers, and Philips could also defend share through bundled service contracts.

The key underwriting risks are technician retention and availability, acquisition integration, and whether growth converts to cash flow after fleet, parts, and working-capital needs. The release provides no sale price, leverage, organic-growth split, or profitability data, so the claimed revenue scale-up cannot establish returns or imply attractive deal multiples. Near term, limited read-through for listed equities. Over 1–3 months, watch for disclosed financing, add-on acquisitions, or evidence of service-contract wins and technician hiring. Over 6–18 months, successful integration could reinforce independent-provider consolidation; deterioration in retention or service quality could reverse that thesis. Contrarian point: geographic expansion and revenue growth may overstate durable value if acquisitions, rather than organic demand and margins, drove most of the increase.

Key Decisions for Investors

• No immediate public-equity trade: the parties are private and transaction terms are undisclosed, leaving no reliable valuation or earnings read-through.
• Treat further acquisitions by Radon under LGP as a watch item for consolidation and potential pricing pressure in independent imaging services; verify deal cadence, organic growth, technician retention, and cash conversion before expressing a view.
• Monitor GE HealthCare, Siemens Healthineers, and Philips for signs of service-contract bundling or pricing responses. A sustained shift in outsourced service wins would matter more than this ownership change alone.
• Falsify the platform-growth thesis if future disclosures indicate weak organic growth, worsening technician attrition, service-quality problems, or acquisition growth without improving cash generation.